Exact Mass: 475.35088440000004
Exact Mass Matches: 475.35088440000004
Found 77 metabolites which its exact mass value is equals to given mass value 475.35088440000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
N-Docosahexaenoyl phenylalanine
N-docosahexaenoyl phenylalanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Phenylalanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl phenylalanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl phenylalanine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
(7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine
C29H49NO4 (475.36613940000007)
(7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Adrenoylcarnitine
C29H49NO4 (475.36613940000007)
Z-Leu-leu-leu-al
C26H41N3O5 (475.30460560000006)
Benzyl N-[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]-N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate
C26H41N3O5 (475.30460560000006)
Z-LLNle-CHO
C26H41N3O5 (475.30460560000006)
2-tetracosanamidoethanesulfonic acid
C26H53NO4S (475.36950980000006)
MG-132
C26H41N3O5 (475.30460560000006)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2160 - Proteasome Inhibitor D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D007976 - Leupeptins D000970 - Antineoplastic Agents C471 - Enzyme Inhibitor
(R)-MG132
C26H41N3O5 (475.30460560000006)
CAR 22:4
C29H49NO4 (475.36613940000007)
Dinoprost
D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue
(2-hydroxyethyl)dimethyl[3-[(1-oxooctadecyl)amino]propyl]ammonium nitrate
1-HYDROXY-N-[4-(2,4-DI-TERT-PENTYLPHENOXY)BUTYL]-2-NAPHTHAMIDE
Z-Leu-Leu-Nle-aldehyde
C26H41N3O5 (475.30460560000006)
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia[1][2].
1-HYDROXY-N-(2-TETRADECYLOXYPHENYL)-2-NAPHTHALENECARBOXAMIDE
Benzyl N-[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]-N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate
C26H41N3O5 (475.30460560000006)
N-hexanoylsphingosine 1-phosphate(2-)
C24H46NO6P-2 (475.30625860000004)
N-[4-methyl-1-[[4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamic acid (phenylmethyl) ester
C26H41N3O5 (475.30460560000006)
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C26H41N3O5 (475.30460560000006)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C26H41N3O5 (475.30460560000006)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C26H41N3O5 (475.30460560000006)
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C26H41N3O5 (475.30460560000006)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C26H41N3O5 (475.30460560000006)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C26H41N3O5 (475.30460560000006)
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-5-(4-oxanylmethyl)-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C26H41N3O5 (475.30460560000006)
2-amino-2-methoxypropane-1,3-diol;(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C24H46NO6P (475.30625860000004)
(E)-3-hydroxy-2-(tridecanoylamino)dodec-4-ene-1-sulfonic acid
C25H49NO5S (475.3331264000001)
3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]undecane-1-sulfonic acid
C25H49NO5S (475.3331264000001)
(E)-3-hydroxy-2-(undecanoylamino)tetradec-4-ene-1-sulfonic acid
C25H49NO5S (475.3331264000001)
(E)-3-hydroxy-2-(pentadecanoylamino)dec-4-ene-1-sulfonic acid
C25H49NO5S (475.3331264000001)
3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]decane-1-sulfonic acid
C25H49NO5S (475.3331264000001)
(E)-3-hydroxy-2-(tetradecanoylamino)undec-4-ene-1-sulfonic acid
C25H49NO5S (475.3331264000001)
(E)-2-(decanoylamino)-3-hydroxypentadec-4-ene-1-sulfonic acid
C25H49NO5S (475.3331264000001)
(E)-2-(dodecanoylamino)-3-hydroxytridec-4-ene-1-sulfonic acid
C25H49NO5S (475.3331264000001)
3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodecane-1-sulfonic acid
C25H49NO5S (475.3331264000001)
(7Z,10Z,13Z,16Z)-docosatetraenoylcarnitine
C29H49NO4 (475.36613940000007)
An O-acylcarnitine having (7Z,10Z,13Z,16Z)-docosatetraenoyl as the acyl substituent.
N-tetracosanoyltaurine
C26H53NO4S (475.36950980000006)
A fatty acid-taurine conjugate derived from tetracosanoic acid.
Benzyl n-[(2s)-4-methyl-1-[[(2r)-4-methyl-1-[[(2s)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
C26H41N3O5 (475.30460560000006)
N-hexanoylsphingosine 1-phosphate(2-)
C24H46NO6P (475.30625860000004)
A ceramide 1-phosphate(2-) in which the ceramide N-acyl group is specified as hexanoyl; major species at pH 7.3.
(2r,3s,4r,6s)-6-{[(1s,2r,5s,7s,10r,11r,14r,17s,18s)-10,17-dimethyl-16,21-dioxahexacyclo[15.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0¹⁴,¹⁸]henicosan-7-yl]oxy}-4-methoxy-2-methyloxan-3-amine
C28H45NO5 (475.32975600000003)